dr Vineet Sehgal
Consultant Pediatric Pulmonologist, IAP Respiratory Chapter

About Author

Omalizumab is a recombinant DNA derived humanized IgG 1k monoclonal antibody that specifically binds to free human IgE in the blood.


  • Adults and children aged 6yearsand above.
  • Confirmed IgE dependent allergic asthma , when serum IgE levels are between 30-700. Not indicated for higher serum IgE levels.
  • Severe uncontrolled asthma despite optimal pharmacological and non pharmacological management (including immunotherapy) and appropriate allergen avoidance.
  • Treatment response should be assessed globally. If no response within 4 months of initiating treatment, unlikely that further administration will be beneficial.
  • Omalizumab is administered subcutaneously once every 2 to 4 weeks. The dosing schedule is according to the serum IgE level and body weight of the patient. Extremely expensive, marketed by Novartis. Consult a pulmnologist or an allergist for treatment.

((ERS ATS Task Force)

Posted On: 26/06/2018

Did you find this post helpful?
Yes (28)
No (14)
28 People found this post helpful.

Read more related information, Click Here

If you have a question on some other topic, Click Here

top hospitals in india
To visit our website please click here
BLK Super Speciality Hospital
Pusa Road, New Delhi-110005
Disclaimer: Although every effort is made to give correct knowledge but legality of every answer can not be guaranteed. All answers are based on professional knowledge of Specialists.